Renal Cell Carcinoma: Molecular Aspects
- 127 Downloads
Renal cell carcinoma is the most common form of the kidney cancer accounting for more than 85% of the cases of which clear cell renal cell carcinoma (ccRCC) is the major histological subtype. The central molecular signature for ccRCC pathogenesis is the biallelic inactivation of VHL gene due to the presence of mutations/hyper-methylation/complete gene loss, which results in the downstream HIF activation. These events lead to increased tyrosine kinase receptor signalling pathways (RAS/MEK/ERK pathway, PI3K/AKT/mTOR pathway and NF-κB pathway), which through their downstream effector proteins causes the cell to proliferate and migrate. Recent studies have shown that VHL inactivation alone is not sufficient to induce the tumor. Mutations in numerous other genes that codes for chromatin modifiers (PBRM1, SETD2 and BAP1) and signalling proteins (PTEN and mTOR) have been identified along with activation of alternate signalling pathways like STAT and Sonic Hedgehog (SHH) pathway. It has also been shown that STAT pathway also works cooperatively with HIF to enhance the tumor progression. However, SHH pathway reactivation resulted in tumor regardless of the VHL status, indicating the complex nature of the tumor at the molecular level. Therefore, understanding the complete aetiology of ccRCC is important for future therapeutics.
KeywordsRenal cell carcinoma Genomics Signalling Von Hippel–Lindau (VHL) Hypoxia inducible factor (HIF) Chromatin modifiers
All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript.
Compliance with Ethical Standards
Conflict of interest
- 17.Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. Pathology and genetics of tumors of urinary system and male genital organs. Lyon: IARCPress; 2004.Google Scholar
- 23.Razafinjatovo C, Bihr S, Mischo A, Vogl U, Schmidinger M, Moch H, et al. Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. BMC Cancer. 2016;16:638.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Razorenova OV, Castellini L, Colavitti R, Edgington LE, Nicolau M, Huang X, et al. The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells. Mol Cell Biol. 2014;34:739–51.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Keefe SM, Hoffman-Censits J, Cohen RB, Mamtani R, Heitjan D, Eliasof S, et al. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. Ann Oncol. 2016;27:1579–85.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Patnaik A, Papadopoulos KP, Tolcher AW, Beeram M, Urien S, Schaaf LJ, et al. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;71:1499-06.CrossRefGoogle Scholar
- 40.Dey N, Das F, Choudhury NG, Mandal CC, Parekh DJ, Block K, et al. microRNA-21 governs TORC1 activation in renal Cancer cell proliferation and invasion. PLoS ONE. 2012;7:3–17.Google Scholar
- 42.Fiorentino M, Gruppioni E, Massari F, Giunchi F, Altimari A, Ciccarese C, et al. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. Oncotarget. 2017;31:7328–35.Google Scholar
- 59.Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen YB, Gonen M, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res. 2013;19:3259–67.CrossRefPubMedPubMedCentralGoogle Scholar